VERADERMICS INC (MANE)
Health Care · biotechnology · NYSE
Veradermics is developing a proprietary, extended-release oral minoxidil treatment aimed at overcoming the safety and efficacy limitations of current hair loss therapies.
What VERADERMICS INC does
Veradermics is a late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for aesthetic and dermatological conditions. Its lead candidate, VDPHL01, is an oral, extended-release formulation of minoxidil designed to treat pattern hair loss in men and women without inducing the cardiac side effects associated with immediate-release formulations.
Themes: hair restoration, dermatology, aesthetic medicine, extended-release drug delivery
Fundamentals
- Price$98.46 as of 2026-08-24 close
- Market cap$4.1B as of 2026-08-24
- P/En/a earnings data not available
- ROE-48.8% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta0.59 as of 2026-08-24
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How MANE compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
MANE is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
34.0 #1583 of 1,704 scored · #225 of 240 in Health Care
Setup 48th: day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 6% of the past ~6 months), which often precedes a bigger move; momentum 43rd: mid-range on the stochastic oscillator; weakest is volume and participation 6th: trading volume is unusually light — only about 50% of its 30-day average.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How VERADERMICS INC looks technically
VERADERMICS INC (MANE): there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day low about 15 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 6% of the past ~6 months), which often precedes a bigger move. Trading volume is unusually light — only about 50% of its 30-day average.
Trend
7
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $110.54 | $110.54 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend) | 11.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30) | 42.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($98.56 to $117.40) — its "stochastic" reading is 23 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 22.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $131.24 | $131.24 |
|---|---|---|
| From the 52-week high | it is 21.7% below its 52-week high (its highest price of the past year) | -21.6% |
| Above the 52-week low | it is 221.3% above its 52-week low (its lowest price of the past year) | +221.3% |
| Below the 52-week high | it is 21.7% below its highest point of the past year | 21.6% |
| Since a 20-day breakout | it made a new 20-day low about 15 trading days ago | 15 sessions |
| Since a 55-day breakout | it made a new 55-day high about 36 trading days ago | 36 sessions |
| All-time high | its highest closing price on record is $131.24 (set on 2026-07-01) | $131.24 |
| Given back of the 52-week move | not available for this company yet | n/a |
| From the all-time high | it is 21.7% below its all-time high | -21.6% |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $32.00 (set on 2026-02-04) | $32.00 |
| Above the all-time low | it is 221.3% above its all-time low | +221.3% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 6% of the past ~6 months), which often precedes a bigger move | 6th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $7.22 between its high and its low — about 7.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $7.22 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $102.14 and $115.39 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $102.14 – $108.76 – $115.39 |
| Typical daily range (% of price) | its price moves about 7.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.0% |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 50% of its 30-day average | 0.50× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.1% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.1% |
|---|---|---|
| Gap filled | a 2.9% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -7.63% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 8.4 percentage points (the stock lost 6.1% while the market gained 2.3%) | -8.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 4.9 percentage points (the stock lost 1.8% while the market gained 3.1%) | -4.9% |
| vs market, 6 months | over the past 6 months this stock beat the market by 120.0 percentage points (the stock gained 131.1% while the market gained 11.1%) | +120.0% |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 1 of the 7 technical signals we can compute for it is currently in a bullish state: outperforming the market over 6 months — these describe past price behaviour, not a forecast | 1 of 7 |
|---|---|---|
| Bearish technical signals | 1 of the 7 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 7 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 14.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 11% above the average price paid since 2026-02-04, so the typical buyer over that stretch is showing a gain. That average is $92.33 — a volume-weighted average of daily closes over 128 sessions, not a true tick-by-tick VWAP. | +11.4% |
|---|
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: MACD just crossed bearish (12/26/9) · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · Most volatile (6%+ typical daily range) · Trading inside the Ichimoku cloud | Learn: adx · rsi · macd · breakout · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.14 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$163.50 range $135.00 – $182.00; median $167.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MANE
- Consensus EPS estimate-$0.5913 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Success is dependent on the successful completion of clinical trials and receiving FDA approval for VDPHL01.","The company is in the late clinical stage and has not yet generated significant commercial revenue, creating uncertainty regarding its future financial viability.","Potential competition from established pharmaceutical companies with greater resources and existing treatment offerings."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
Cluster buying: 5 different insiders reported open-market purchases (SEC code P) of MANE within a 30-day window between 2026-02-04 and 2026-02-06. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Most recent open-market transaction: 2026-02-06. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MANE's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding MANE as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 5,666,147
- Reported value $357,817,188
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
MANE had 4,820,395 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
MANE had 11.5% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6.92 days to cover at the same settlement.
- Reported short interest (shares) 4,820,395
- Short interest (% of shares outstanding) 11.5%
- Prior settlement (shares) 3,936,348
- Reported change 22.46%
- Days to cover (reported) 6.92
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Eli Lilly (LLY)
- Pfizer (PFE)
- Johnson & Johnson (JNJ)
- AbbVie (ABBV)
- Bausch Health (BHC)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MANE vs…
Frequently asked questions
What does VERADERMICS INC (MANE) do?
Veradermics is a late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for aesthetic and dermatological conditions. Its lead candidate, VDPHL01, is an oral, extended-release formulation of minoxidil designed to treat pattern hair loss in men and women without inducing the cardiac side effects associated with immediate-release formulations.
What sector is VERADERMICS INC (MANE) in?
VERADERMICS INC (MANE) is classified in the Health Care sector. Its industry is biotechnology. It trades on NYSE.
Who are VERADERMICS INC's (MANE) competitors?
Notable peers of VERADERMICS INC (MANE) include Eli Lilly, Pfizer, Johnson & Johnson, AbbVie and Bausch Health. This peer set is informational only — not financial advice.
Is VERADERMICS INC (MANE) overbought or oversold right now?
VERADERMICS INC (MANE) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 43, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MANE come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.